The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksShire Share News (SHP)

  • There is currently no data for SHP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TOP NEWS: Shire Income Up In 2nd-Quarter Ahead Of Takeover By Takeda

Tue, 31st Jul 2018 12:51

LONDON (Alliance News) - Irish biotechnology company Shire PLC on Tuesday posted a more than doubled pretax income in the second quarter, ahead of its upcoming takeover by Takeda Pharmaceutical Co Ltd.

In the three months to June 30, Shire recorded pretax income from continuing operations, excluding equity earnings, of USD734.2 million. This compares with a USD261.5 million income for the same quarter in 2017.

The company's revenue for the period was USD3.92 billion, up from USD3.75 billion the year before. Product sales made up the bulk of this, increasing 6% to USD3.81 billion from USD3.59 billion.

Immunology led product sales growth, climbing 13%, alongside a 61% rise in internal medicine sales and a 75% growth in Ophthalmics sales.

Royalties and other revenue dropped 28% to USD111 million from USD154 million due to lower royalties from thyroid drug Sensipar.

Revenue from ADHD drug Adderall XR was reclassified to product sales from royalty revenue, alongside other changes under the new accounting standard.

The company said that it will pay a dividend per share of 5.60 US cents for the interim, up 10% from 5.09 cents in 2017.

Shire intends to sell its oncology franchise to Servier SAS in the upcoming third quarter of 2018. At present, Shire's guidance 2018 is unchanged but it will be updated once the franchise is sold. The company said its 2020 guidance is likewise unchanged but has yet to be updated to include the sale of oncology.

"During the quarter, our board reached an agreement with the Takeda board on the terms of a recommended offer for Takeda to acquire Shire. The acquisition is expected to close in the first half of 2019, subject to shareholder approval of both companies and additional regulatory approvals. In the meantime, we remain resolutely focused on execution as these results demonstrate," said Shire Chief Executive Flemming Ornskov.

Shire agreed a takeover by Takeda in early May and gained unconditional clearance from the US Federal Trade Commission at the start of this month. The deal values Shire at GBP46.00 billion.

Shares in Shire were up 0.5% at 4,335.00 pence on Tuesday.

More News
14 Sep 2018 09:15

Shire gains as takeover approved by China

(Sharecast News) - Japan's Takeda Pharmaceutical has received regulatory approval from China for its $62bn takeover of London-listed Shire.

Read more
13 Sep 2018 10:56

Takada eyeing potential Shire asset sales to pay down debt

(Sharecast News) - Takeda Pharmaceutical may try and sell Shire's dry-eye drug once it completes the $62bn takeover purchase of the UK-listed biotech, according to a report on Thursday.

Read more
13 Sep 2018 08:25

Takeda weighs sale of Shire's eye care business to cut debt- Bloomberg

Sept 13 (Reuters) - Japan's Takeda Pharmaceutical is considering selling Shire Plc's eye care business once it closes its $62 billion purchase of the London-listed drugmaker, as it looks a

Read more
12 Sep 2018 16:12

Takeda to pack up Illinois HQ, nearly 1,000 workers to be affected

Sept 12 (Reuters) - Japan's Takeda Pharmaceutical Co Ltd said on Wednesday it plans to shut its U.S. headquarters in Deerfield, Illinois and move it to the greater Boston area, following the —

Read more
12 Sep 2018 07:22

Shire gets EC marketing authorisation for 'VEYVONDI' treatment

(Sharecast News) - Rare diseases specialist Shire announced on Wednesday that the European Commission has granted marketing authorisation for 'VEYVONDI', for the treatment of bleeding events and the treatment and prevention of surgical bleeding in adults with von Willebrand disease, when desmopressin treatment alone is ineffective or not indicated.

Read more
10 Sep 2018 16:08

Two Shire Subsidiaries Receive Majority Early Offers For Senior Notes

LONDON (Alliance News) - Biotechnology company Shire PLC on Monday said two of its subsidiaries, Baxalta Inc and Shire Acquisitions Investments Ireland DAC, had received early offers for a of the

Read more
7 Sep 2018 09:33

BROKER RATINGS SUMMARY: Goldman Cuts Burberry; Redburn Cuts HSBC

LONDON (Alliance News) - The following London-listed shares received analyst recommendations Friday morning and Thursday:----------FTSE 100----------GOLDMAN CUTS GROUP TO BUY -

Read more
6 Sep 2018 11:20

European Shares Reverse Early Losses On Improving Sentiment

BRUSSELS/FRANKFURT/PARIS (Alliance News) - European stocks were marginally higher on Thursday after having fallen to a five-month low earlier in the day.Sentiment improved somewhat after US

Read more
6 Sep 2018 10:54

TOP NEWS: Shire Buys Swiss Plasma Collection Firm Sanaplasma

LONDON (Alliance News) - Shire PLC said Thursday it has bought Swiss source plasma collection company sanaplasma AG for an undisclosed sum.The FTSE 100 pharmaceutical giant said that the is

Read more
6 Sep 2018 10:52

Shire buys Swiss plasma firm sanaplasma for undisclosed sum

(Sharecast News) - Pharmaceuticals giant Shire on Thursday said it had bought Switzerland's sanaplasma AG for an undisclosed sum.

Read more
6 Sep 2018 07:48

UPDATE 1-UK Stocks-Factors to watch on Sept. 6

Sept 6 (Reuters) - Britain's FTSE 100 futures were down 0.1 percent ahead of the cash market open on Thursday. * DIXONS CARPHONE: Dixons Carphone, the troubled British electricals and a

Read more
31 Aug 2018 10:16

Shire Completes USD2.4 Billion Oncology Franchise Sale To Servier

LONDON (Alliance News) - Irish biotechnology giant Shire PLC said Friday it has completed the sale of its oncology franchise to Servier SAS.The FTSE 100-listed company sold its franchise, a

Read more
31 Aug 2018 09:07

Shire completes $2.4bn oncology sale to Servier

(Sharecast News) - Shire has completed the sale of its oncology franchise to Servier for $2.4bn, it announced on Friday.

Read more
24 Aug 2018 14:04

TOP NEWS: Shire Launches Tender Offer To Buy Up To USD2 Billion Notes (ALLISS)

LONDON (Alliance News) - Biotechnology company Shire PLC on Friday said its wholly-owned subsidiaries Baxalta and Shire Acquisitions Investments Ireland DAC launched a tender offer to repurchase a

Read more
24 Aug 2018 13:54

MARKET ANALYSIS: Futures Pointing To Initial Strength On Wall Street

WASHINGTON (Alliance News) - The major US index futures are pointing to a higher opening on Friday, with stocks likely to move to the upside after ending the previous session modestly upward on a

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.